CSI Market
Sign In | Register

Standard Biotools Inc (LAB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LAB Annual Cash Flow →
Quarterly cash flow trends provide additional context on Standard Biotools Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income64.16
Depreciation & amortization5.38
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Bargain Purchase, Gain Recognized, Amount5.89
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-1.41
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Project168.08
Share-based Compensation21.93
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Fair Value Liabilities Measured On Recurring Basis Gain Loss Included In Other Income-
Gain From Extinguishment Of Convertible Preferred Stock Warrants-
Write Off Of Debt Discount Upon Note Repayment-
Business Combination Fair Value of Inventory-
Gain Losson Escrow Settlement-
Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost-
Loss On Forward Sale Of Stock-
Debt Securities Unrealized Gain Loss-
Increase Decrease In Contract With Customer Liability-29.93
Operating Lease Right Of Use Asset Amortization Expense1.36
Non Cash Lease Expense-
Change In Fair Value Of Contingent Consideration-
Income taxes0.00
Unrealized Gain (Loss) on Investments-1.36
Increase (Decrease) in Accounts Receivable0.61
Increase (Decrease) in Accounts Payable0.44
Increase (Decrease) in Accrued Liabilities-14.14
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.63
Other Working Capital-0.01
Other Noncash Income (Expense)0.00
Other net1.84
Payments for (Proceeds from) Other Operating Activities-447.41
Discontinued operations136.46
Net Cash flow from Operating Activities-56.91
Investing Activities
Capital Expenditures-0.91
Sale of Capital Items0.00
Payments to Acquire Short-term Investments-127.21
Payments to Acquire Marketable Securities-0.84
Real Estate Investments0.00
License Agreement Rights-
Proceeds From Research And Development Grant-
Purchases Of Short- Term Marketable Debt Securities-127.21
Purchases Of Long- Term Marketable Debt Securities-58.52
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Maturities, Prepayments and Calls of Other Investments-56.85
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates3.09
Proceeds from Divestiture of Businesses388.21
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities205.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.20
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.38
Other net0.00
Proceeds From Exercise Of Convertible Preferred Stock Warrants And Issuance Of Convertible Preferred Stock Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.18
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-57.82
Total Cash Flow148.82
4 historic quarters locked

Sign in to unlock the full Standard Biotools Inc cash flow history.

Sign In Create Free Account

About Standard Biotools Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 5, 2026
  • Source: lab-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-335103

Figures are derived from filed reports and may be restated. Historical data is subject to revision.